Medcast Series

In this MEDCast series, pharmacists Justin Arnall, PharmD, BCOP, Breanna Taylor, PharmD, BCOP, and Jeff Goff, RPh, MS, unpack how the pharmacist's role has expanded as IV iron indications spread beyond nephrology and GI into cardiology and oncology. The trio moves from the shifting clinical landscape and formulary decisionmaking, to the access barriers created by payer-driven step therapy and prior authorizations, to the operational realities of dosing structure, chair time, and preparation burden that shape which products infusion centers can realistically deliver, and finally to safety considerations like hypophosphatemia risk and infusion reactions.

Millions of Americans live with excessive daytime sleepiness (EDS) caused by narcolepsy or obstructive sleep apnea (OSA), yet many remain undertreated, with gaps in identification, management, and access persisting in clinical practice. In this series, W. Christopher Winter, MD (Charlottesville Neurology and Sleep Medicine), and a clinical pharmacist provide an in-depth discussion on solriamfetol (Sunosi; Axsome), the first and only dopamine-norepinephrine reuptake inhibitor (DNRI) approved specifically for EDS in these conditions.

In this Pharmacy Times MEDCast, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, examines the pharmacist's role in treating worsening congestion in heart failure with subcutaneous furosemide (Furoscix). The series moves from the clinical problem—why oral furosemide fails when patients need it most—through Furoscix's mechanism, patient selection, and monitoring into how pharmacists coordinate care from identification to discharge and build a diuresis model from scratch. Beavers previews the ReadyFlow autoinjector, a higher-concentration formulation that delivers a dose in seconds rather than 5 hours, and closes with practical takeaways on congestion-monitoring technologies, self-education, and pharmacist advocacy in preventing heart failure readmissions.